US › Healthcare

Bicycle Therapeutics Ltd (BCYC)

US · Healthcare · Biotechnology

$3.68+1.10%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$629,000

Revenue YoY

-78.5%

Net profit

$-50.3M

EPS

$-0.72

EPS estimate

$-0.37

Net margin

-8,002.1%

EPS came in at -0.72 against a street estimate of -0.37 — a miss of 94.6%.

Key statistics

Market cap

$270.2M

Forward P/E

0.0

P/B

0.53

Book value

$7.31

EPS (TTM)

$-2.73

52-week high

$9.16

52-week low

$3.75

50-day MA

$4.13

200-day MA

$5.14

Beta

1.54

Analyst view

Analysts rate Bicycle Therapeutics Ltd a buy (10 buy, 3 hold, 0 sell out of 13) with an average price target of $9.50.

Shareholding

Insiders

4.47%

Institutions

71.88%

Largest institutional holders

Fund	Stake
Baker Bros Advisors LP	15.55%
FCPM III SERVICES BV	4.96%
Armistice Capital, LLC	4.85%
Long Focus Capital Management, LLC	4.73%
Acadian Asset Management LLC	2.81%
Siren, L.L.C.	2.23%
GSK PLC	2.19%
T. Rowe Price Associates, Inc.	1.47%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Bicycle Therapeutics Ltd — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.